title: Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
abstract: Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.
authors.affiliation: aAdult Mesenchymal Tumor Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan bDepartment of Oncology, General Hospital of Agrigento, Agrigento cDepartment of Oncology, Ospedale Civile SS Annunziata Sassari, Sassari dMedical Oncology Unit, University Hospital S. Chiara, Pisa eDepartment of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy fDepartment of Oncology, University College of London Hospital gSarcoma Unit, Royal Marsden, London, UK hCentre Leon Berard, Lyon iInstitut Gustave Roussy, Villejuif, France.
authors.forename: Roberta
authors.initials: R
authors.lastname: Sanfilippo
authors.forename: Palma
authors.initials: P
authors.lastname: Dileo
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Anastasia
authors.initials: A
authors.lastname: Constantinidou
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.forename: Charlotte
authors.initials: C
authors.lastname: Benson
authors.forename: Laura
authors.initials: L
authors.lastname: Vizzini
authors.forename: Marianna
authors.initials: M
authors.lastname: Contu
authors.forename: Giacomo G
authors.initials: GG
authors.lastname: Baldi
authors.forename: Angelo P
authors.initials: AP
authors.lastname: Dei Tos
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Casali
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004149:Dioxoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013584:Sarcoma, Synovial / Q000188:drug therapy* / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D000077606:Trabectedin
chemical_list: D000970:Antineoplastic Agents; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin